Reduced Norepinephrine Transporter Binding in Parkinson’s disease with dopa Responsive Freezing Gait

J. Lucas McKay, Jonathan Nye, Felicia C. Goldstein, Barbara Sommerfeld, Yoland Smith, David Weinshenker, Stewart A. Factor
doi: https://doi.org/10.1101/2022.03.14.22272365

Abstract

Freezing of gait (FOG) is a major cause of falling and leads to loss of independence in Parkinson’s disease (PD). The pathophysiology of FOG is poorly understood – although there is a hypothesized link with NE systems. PD-FOG can present in levodopa-responsive and unresponsive forms.

We examined NE transporter (NET) binding via brain positron emission tomography (PET) to evaluate changes in NET density associated with FOG using the high affinity selective NET antagonist radioligand [11C]MeNER (2S,3S)(2-[α-(2-methoxyphenoxy)benzyl]morpholine) in N=52 parkinsonian patients. We used a rigorous levodopa challenge paradigm to characterize patients as non-freezing PD (NO-FOG, N=16), levodopa responsive freezing (OFF-FOG, N=10), levodopa-unresponsive freezing (ONOFF-FOG, N=21), and primary progressive freezing of gait (PP-FOG, N=5).

Linear mixed models identified significant reductions in whole brain NET binding in the OFF-FOG group compared to the NO-FOG group (−16.8%, P=0.021). Additional contrasts tested post-hoc identified trends toward increased NET expression in ONOFF-FOG vs. OFF-FOG (≈10%; P=0.123). Linear mixed models with interaction terms identified significantly reduced NET binding in right thalamus in the OFF-FOG group (P=0.038). A linear regression analysis identified an association between reduced NET binding and more severe NFOG-Q score only in the OFF-FOG group (P=0.022).

This is the first study to examine brain noradrenergic innervation using NET-PET in PD patients with and without FOG. Based on the normal regional distribution of noradrenergic innervation and pathological studies in the thalamus of PD patients, the implications of our findings suggest that noradrenergic limbic pathways may play a key role in OFF-FOG in PD. This finding could have implications for clinical subtyping of FOG as well as development of therapies.

Introduction

Freezing of gait (FOG), defined as “brief, episodic absence or marked reduction of forward progression of the feet despite intention to walk”, is a common, disabling feature of Parkinson’s disease (PD)1. It is a major reason for falling and injury and leads to loss of independence and poor quality of life2,3. FOG is considered a cardinal feature of PD with independent progression4. The pathophysiology is poorly understood. Several system related theories have been proposed but the potential contribution of norepinephrine (NE) has historically received a great deal of interest and has led to a drug approval in one country for this purpose. NE is a catecholamine that has widespread distribution in the brain and appears to play a key role in arousal, attention, stress responses, mood, and cognition5-8.

The primary NE nucleus in brain is the locus coeruleus (LC), which projects to subcortical and cortical regions, including motor, premotor and associative regions of the frontal cortex, thalamus, hypothalamus, brainstem, amygdala, hippocampus, and cerebellum9-13. The LC is one of the earliest sites of α-synuclein pathology in the brain and undergoes catastrophic degeneration later in PD14-17. LC terminal degeneration precedes cell body loss18 and is associated with decreased tissue NE levels in LC projection regions13,19. Studies in animal models and patients indicate that the loss of LC-NE may exacerbate motor symptoms of PD, contribute to dopamine neuron degeneration, and attenuate the therapeutic effects of levodopa20-25.

The hypothesis linking NE to FOG is primarily based on data showing that L-DOPS (droxidopa), a synthetic precursor to NE, reduces the symptom complex. L-DOPS treatment produced marked to moderate improvement of FOG in 25% of patients in a study from the 1980’s26,27, and similar improvement was reported in atypical parkinsonian cases28. However, these findings are controversial and have not been replicated4. This work led to approval of droxidopa in Japan for FOG two decades ago. L-DOPS has also been examined and recently approved in the U.S. for orthostatic hypotension29. Other noradrenergic drugs including atomoxetine and stimulants appear to be effective in some patients with FOG30-32. Further, an association between FOG and NE deficit was shown in a study utilizing 6-[18F]fluoro-l-m-tyrosine (FMT) PET (a marker for NE metabolism). This study showed that decreased FMT uptake in LC was strongly correlated with increased self-reported FOG severity in PD patients33. This observation must be confirmed through more comprehensive studies in larger cohorts of patients. Finally, the relationship between FOG and anxiety is also consistent with the link between FOG and NE34,35. FOG can be elicited in situations of elevated stress36, which increases LC activity, NE release and arousal in animal models6,37-39. This suggests the hypothesis that a dysregulated LC-NE system may have aberrant responses to stress in PD that could, in turn, trigger FOG episodes.

In this study we examined NE transporter (NET) binding via positron emission tomography (PET) to evaluate changes in NET density associated with FOG. NET is a member of the Na+/Cl-dependent neurotransmitter transporter gene family located on the nerve terminals as well as the somatodendritic field of NE neurons and serves as a proxy for LC terminal integrity. We used the radioligand [11C]MeNER (2S,3S) (2-[α-(2-methoxyphenoxy) benzyl]morpholine), which has high affinity and is a selective antagonist for NET 40,41, to compare NET availability across PD patients with and without FOG, as well as in a small group of patients with non-PD FOG (referred to as primary progressive Freezing of Gait)42. We also separated PD-FOG patients into those responsive and non-responsive to levodopa43.

Materials and Methods

Study population

Study patients were recruited from the Emory Movement Disorders Clinic and provided written informed consent according to procedures approved by the Institutional Review Board of Emory University. Inclusion criteria for PD were: Age≥18 years; PD diagnosis defined by the United Kingdom Brain Bank criteria44; Hoehn & Yahr stage IV or higher in the OFF state; levodopa responsive; capable of signing a consent document and willing to participate in all aspects of the study. Inclusion criteria specific to participants with FOG were FOG noted in medical history and confirmed visually by examiner. Patients with primary progressive freezing gait (PP-FOG) diagnosed based on previously reported criteria45 were included; while patients previously treated with dopamine receptor blocking medications; or with neurological or orthopedic disorders interfering with gait including vascular parkinsonism; dementia or other medical problems precluding completion of study protocol were excluded.

Levodopa challenge paradigm

The details of the levodopa paradigm challenge have been published elsewhere43. In brief, patients came to clinic in the practically defined “OFF” state >12 hours after last intake of antiparkinsonian medications46. They were assessed for motor symptoms using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale part III motor examination (MDS-UPDRS-III). After the assessment, patients were administered a levodopa equivalent dose (LED) greater than their typical morning dose. The assessment was repeated after patients reached their full “ON” state.

FOG group assignment

We classified each PD patient into one of three study groups based on history of the presence of FOG along with scores on the MDS UPDRS-III item 11 “Freezing of Gait” exam in each of the “OFF” and “ON” medication states. Participants who had no history of FOG and received a score of zero on item 11 in both medication states were classified as “no freezing,” or “NO-FOG.” Participants who received a nonzero score on item 11 in the “OFF” medication state but a zero score in the “ON” medication state were classified as “OFF-FOG.” Participants who received a nonzero score on item 11 in both medication states were classified as “ONOFF-FOG.” Patients in the primary progressive Freezing of Gait group were classified as “PP-FOG.”

[11C]MeNER-PET Imaging

Patients were assessed with NET-PET imaging on a separate testing day. The typical interval between levodopa challenge testing and NET-PET imaging was 2.2 ± 2.8 months. Urine pregnancy tests were obtained within 24 hours prior to injection of [11C]MeNER for female subjects, unless no menses during the past consecutive 12 months. Any noradrenergic medications were held for a duration based on the half-life. A telephone contact seven days post imaging session was made to assess for any adverse events. Patients maintained their typical medication schedule for NET-PET imaging.

Scanning Procedure

[11C]MeNER was synthesized by methylation of (S,S)-2-(α-(2-Methoxyphenoxy)benzyl)morpholine (MeNER), an analogue of the selective norepinephrine reuptake inhibitor (S,S)-reboxetine, as previously described47. The administered activity ranged from 570 to 832 MBq delivered intravenously with an average specific activity of 32 ± 12 GBq/µmol, resulting in an injected mass ranging between 3.4 and 17 µg.

Imaging Procedures

PET data was collected on a High-Resolution Research Tomography (CTI, Inc. Knoxville, TN) at the Emory Center for Systems Imaging. The PET system has a 2.5mm spatial resolution and 10-fold higher sensitivity than current clinical PET cameras48. Subjects had a venous catheter placed in their forearm and were administered [11C]MENeR in a quiet uptake room for 60 minutes. Subjects were then placed supine on the imaging table with their head lightly restrained using Velcro straps, and 30 min of PET data was collected. PET data were divided into six frames, each five minutes duration and reconstructed with an ordinary Poisson ordered-subset expectation maximization (OP-OSEM) algorithm (6 iterations, 16 subsets) including scatter and attenuation correction.

Structural MRI images were acquired on a 3T Siemens Prisma scanner with a 32-channel receiver array head coil. A standard whole-brain 3D T1-weighted MPRAGE sequence49 recommended for brain structure morphometric analysis50 (FOV = 256 mm; TR/TI/TE/FA = 2530 ms/1100 ms/3 ms/8°; 1 mm X 1 mm X 1 mm resolution; time of acquisition ∼ 9 minutes) was acquired to provide anatomic detail. Foam padding was utilized to minimize head motion. These data were be used for normalization of PET data to the standard Montreal Neurological Institute analysis space.

Image Analysis

PET data was corrected for inter-subject motion and co-registered to their structural MRI scan by optimization of the mutual information metric. MRI structural data were then spatially normalized to the Montreal Neurological Institute (MNI T2 152) template with SPM8’s segment option and default parameters. The inverse non-linear transform was used to map regions of interest from the Anatomical Automatic Labeling template51 including the frontal lobe, left and right thalamus, temporal lobe, LC and cerebellum. Regional standardized uptake value ratios (SUVR) were extracted from the reconstructed PET data normalized to the cerebellum33. We have shown that this approach is highly correlated with NET binding density in structurally similar analogue based on reboxitine52. Imaging technologists and those assessing results were blinded to the their group assignment.

Statistical Analysis

All summary statistics are presented as mean (standard deviation) or frequency (percentage). Clinical and demographic variables were compared across study groups using univariate tests (Chi-squared, ANOVA). Variation in NET binding across study groups was assessed with a linear mixed model with fixed effects for study group (NO-FOG, OFF-FOG, ONOFF-FOG, and PP-FOG, with NO-FOG as the reference group) and brain region (Frontal cortices, left thalamus, right thalamus, locus ceruleus, temporal lobes, with frontal cortices as the reference group) and a random effect for patient. Subsequent models evaluated sensitivity of main results to inclusion of covariates identified as marginally significant in univariate tests (sex, duration). Region-specific group effects were assessed with an additional linear mixed model with region by group interaction terms. Linear mixed models were implemented in LmerTest::lme4 in R software and fitted using restricted maximum likelihood. Linear regression models were applied to evaluate associations between NET expression and self-reported FOG severity (NFOG-Q) score in regions identified as varying with FOG group (stats::lm in R software). All statistical analyses were performed in R v4.1.1 at alpha = 0.05.

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Results

Clinical and demographic characteristics

A total of N=60 patients were enrolled and assessed with levodopa challenge. Of these, PET data was subsequently obtained for 52: Sixteen were classified as NO-FOG, 10 as OFF-FOG, and 21 as ONOFF-FOG. The remaining five patients were PP-FOG. Clinical and demographic characteristics are presented in Table 1. No statistically significant differences in frequency of missing data were observed across study groups (Supplemental Information). No statistically significant differences in clinical or demographic variables were observed between groups; with the exception of N-FOGQ score and MDS-UPDRS-III FOG item scores (expected from the design) and marginally significant effects of sex (P=0.05) and disease duration (P=0.08). Higher levels of anxiety were reported among those with freezing (average scores of 10.8±8.2 vs. 8.4±6.1 on the Beck Anxiety Inventory); however, this contrast was not statistically significant (P=0.69, ANOVA).

View this table:
Table 1.

Demographic and clinical characteristics of the study sample.

NET binding

In general, a similar pattern of variation in NET binding across study groups was observed across all brain regions of interest. The lowest levels of NET SUVR values were observed in the OFF-FOG group, followed by PP-FOG, ONOFF-FOG, and NO-FOG, respectively. (Region-specific values are summarized in Supplemental Information; Table S1). Linear mixed models identified significant reductions in whole brain NET binding in the OFF-FOG group compared to the NO-FOG group (change in SUVR -16.8%, P=0.021; Figure 1). Additional contrasts tested post-hoc identified trends toward increased NET binding in ONOFF-FOG vs. OFF-FOG (≈10%; P=0.123). No trends were observed for the PP-FOG group. Models controlling for sex and disease duration produced very similar results (−16.1% and -14.4%, respectively), although the contrast between OFF-FOG and NO-FOG was only marginally significant (P=0.054) when controlling for duration. Linear mixed models with interaction terms between study group and brain region identified a significant reduction in NET binding in right thalamus in the OFF-FOG group (P=0.038). A similar reduction of smaller magnitude was observed in left thalamus (P=0.157).

Figure 1.
Figure 1.

Variation in NET binding with FOG classification. A linear mixed model identified statistically significant reduction in NET binding across all brain regions in the OFF-FOG group vs. the NO-FOG group.

Right thalamus NET expression and NFOG-Q score

Because of the strong interaction observed between NET binding and OFF-FOG group in the right thalamus, we tested whether NET abundance in this area was associated with self-reported FOG severity as measured on NFOG-Q. The PP-FOG group was excluded from this analysis due to the small number of cases. A linear regression of NFOG-Q score onto right thalamus NET availability identified a statistically significant negative relationship, with reduced NET associated with more severe NFOG-Q score in the OFF-FOG group (P=0.022), but not in the other groups (Figure 2). The overall variation in NFOG-Q score explained by NET binding with interaction terms for group was R2adj = 0.88. Similar relationships were observed in a model with the square root of NFOG-Q score as the dependent variable to stabilize variance (Supplemental Information).

Figure 2.
Figure 2.

Association between NET binding in right thalamus and NFOG-Q score. Linear regression identified a statistically significant association between NET binding and NFOG-Q among OFF-FOG (solid line) but not among the other groups (dashed lines).

Additional analyses

Similar results were obtained with additional linear mixed models performed post-hoc that: 1) considered only those cases with imaging within 3 months of levodopa challenge (NET binding in OFF-FOG vs. NO-FOG, -16.0%, P=0.043), 2) that excluded the PP-FOG group (−16.8%, P=0.027), and 3) that excluded the LC (−17.2%, P=0.020).

Discussion

There is mounting evidence supporting a role for extranigral noradrenergic (NA) systems in the development of FOG in PD. This is a first look at the use of NET-PET imaging using the ligand [11C]MeNER as a tool to examine the role of NA denervation in PD-FOG. We examined whole brain NET binding via PET to evaluate changes in NET density associated with FOG; and particularly, in relation to FOG responsiveness to levodopa. We scanned 47 PD patients (16 NO-FOG, 10 OFF-FOG, 21 ONOFF-FOG) and 5 patients with primary progressive freezing gait (PP-FOG). We found significantly decreased whole-brain NET binding in the OFF-FOG group compared to NO-FOG (P=0.021). Importantly, we showed that this deficit was specific to OFF-FOG; patients with ONOFF-FOG or PP-FOG showed NET binding comparable to those without FOG. Additional region-specific comparisons revealed decreased binding in the right thalamus (P=0.038) with a trend for the left thalamus (P=0.16), in the PD OFF-FOG group. These findings support the hypothesis that a loss of NA innervation, perhaps particularly to the thalamus, may contribute to levodopa responsive FOG (OFF-FOG) in PD patients. The results also add to previous findings suggesting a connection between NA dysfunction and FOG. Further, this decreased NA innervation may relate to the recently reported increase in CSF Aβ42 amyloid in PD-FOG patients53 as previously suggested by studies in non-human primates and several transgenic rodent models where the reduction of NE contributed to increased Aβ pathology54-56. Interestingly, the increased amyloid aggregation in these models was reversed by using droxidopa57.

Structural and functional changes in the thalamus in FOG

This work adds to a growing body of knowledge demonstrating structural and functional changes in the thalamus – and in the connections of the thalamus to other brain regions – in PD patients with FOG. In a prospective MRI neuroimaging study, D’Cruz et al58 showed local inflations in bilateral thalami in patients who presented with or would later develop FOG. These inflations involved medial thalamic sub-nuclei volumes which are highly innervated by NA pathways. Resting-state analyses at baseline further revealed that patients who would go on to develop FOG had thalamo-cortical coupling with limbic and cognitive regions initially stronger than that among patients who would not go on to develop FOG. This initial increased coupling exhibited a marked reduction over the two years. The authors hypothesized that many of these changes may have been compensatory in nature, with increased reliance on non-motor thalamic networks, particularly limbic connections, in PD patients with FOG; after initial success, decompensation occurred, and FOG would emerge over the course of disease progression.

Other studies have shown several anatomical changes in connections between the thalamus and other brain regions in FOG, including some known to be crucial for balance and gait. These include diminished structural connectivity between the thalamus and mesencephalic locomotor region and reduced thalamic fiber tracts in the right hemisphere in FOG59 and more pronounced white matter abnormalities in multiple tracts connecting to the thalamus in FOG60. It has also been shown that FOG episodes are associated with decreased anterior thalamic Blood-Oxygen-Level-Dependent (BOLD) signal, potentially associated with paroxysmal reductions in mesencephalic locomotor region activity61,62.

Our results imply that there is decreased NA innervation of the thalamus in patients with levodopa responsive FOG, which strongly suggests that interaction between NA sensory signaling and dopaminergic movement regulation is particularly important for OFF-FOG phenotype. It is possible that in the presence of dopamine replacement, some patients are able to successfully leverage non-motor regions of basal-ganglia-thalamocortical loops to compensate for impaired NA motor – specifically gait and balance – pathways. It is conceivable that this could lead to compensatory “inflation” of these areas as described by D’Cruz and colleagues, and that additional damage to other tracts impinging on the thalamus would impact this compensation. However, because the majority of these studies did not classify patients by FOG levodopa responsive state, it is difficult to draw firm conclusions. What appears clear is that there is a class of patients with greater NA deficits in the thalamus who do not experience FOG in the presence of adequate dopamine.

Noradrenergic innervation of the thalamus

Noradrenergic innervation of the thalamus has been examined in monkey and human in some detail. In a study of two nonhuman primates, NA axon maps were generated with dopamine β-hydroxylase (DβH) and NET immunohistochemistry, and in vitro quantitative autoradiography for alpha-1 and alpha-2 adrenergic receptor densities63. The distribution patterns of DβH, NET, and adrenergic receptors were very similar with some modest variation noted. The most densely innervated thalamic regions were the midline, caudal intralaminar (paracentral and parafascicular), and medial mediodorsal nuclei. NA axons were present at moderate levels within the anterior nuclei, while the ventral motor thalamic nuclei exhibited moderate to low NA innervation. The sensory relay nuclei were generally less innervated. The visual relay nucleus, dorsal geniculate nucleus displayed the lowest NA innervation. These findings were concordant with postmortem human results13,64,65.

Although NET-PET does not provide the spatial resolution to distinguish the distribution of NET binding within the various thalamic nuclei, the impact of decreased thalamic NET binding can be speculated based on these findings and considering the systems thought to be involved in freezing, including motor, visual, cognitive, and limbic circuits66. It is noteworthy that the highly NA-innervated caudal intralaminar regions include predominantly thalamic neurons that project heavily to associative and limbic striatum67,68. The dense NA axonal innervation of these thalamic nuclei may allow for an indirect NA modulation of basal ganglia activity across motor and non-motor functional domains63. Furthermore, these densely innervated regions are known to receive extensive cholinergic innervation from the pedunculopontine tegmental area64, a cholinergic brain network that is also severely disrupted in PD69.

Thalamic Pathology in PD

Thalamic pathology has been studied in PD using neurochemical and anatomic methods. Unfortunately, none of these studies examined PD-FOG separately. Nevertheless, they provide some important relevant information. Pifl et al13 reported widespread loss of thalamic NE including motor (>85%), limbic (>/= 78%), and intralaminar/midline nuclei in PD compared to controls. The widespread nature of the loss of thalamic NE in PD is likely the result of the well-established degeneration of the LC17. Rub et al 70 showed that areas of increased Lewy inclusion pathology in the thalamus roughly corresponded to areas of dense NA innervation. These findings indicate that the burden of the PD-related pathology is seen in nuclei representing essential parts of the motor and limbic circuit70.

Limbic circuits and FOG

These results are consistent with the hypothesis that abnormal limbic-striatum connectivity may interfere with processing specific anxiety provoking situations that lead to FOG – particularly OFF-FOG. As shown, the thalamic NA system is closely linked to limbic circuits and, in turn, we have shown in this study a link between NA changes and FOG. Other studies have shown a connection between FOG and limbic circuit changes. The limbic circuit plays a critical role in generating adequate emotional and behavioral responses, regulation of motivational processes and social behavior, and emotional processing, particularly of stimuli that induce anxiety and depression, including in PD71-75, all of which are essential for learning and memory. It has been suggested that this circuit is connected to the development of FOG based on several reports of worsening anxiety and depression in PD-FOG patients compared to PD-NOFOG34,35. Further, greater situational anxiety is also associated with worse FOG severity35. Imaging studies 66,76 have found that connectivity between the amygdala and striatum was significantly increased in freezers compared to non-freezers. It is suggested that the increased connectivity between the limbic circuit and striatum represents over-integration between these normally segregated networks which may lead to transient overload of motor network processing, that is the already dopamine depleted, leading to transient increased inhibitory input of the basal ganglion leading to motor breakdown and freezing77,78. In addition, anti-coupling between the cortical and subcortical limbic network and within the subcortical network was marked during freezing66. This might suggest there is an abnormality in processing specific anxiety provoking situations that lead to FOG, particularly OFF-FOG, and that this relates to abnormal limbic-striatum connectivity. Considering that anxiety and panic frequently occur as manifestations of off episodes79 it makes sense that the limbic circuitry would relate to the OFF-FOG group specifically.

ONOFF vs OFF FOG in PD: Different pathophysiology?

The results of this study provide additional evidence supporting the hypothesis that OFF-FOG and ONOFF-FOG result from distinct pathophysiology. We have shown that OFF-FOG relates to hallucinatory phenomena while ONOFF-FOG is associated with distinct cognitive features – with the implication that these two types are associated with distinct pathophysiology in regions outside the basal ganglia80. We have also shown that axial and lower limb parkinsonian signs are also less severe and more levodopa responsive in OFF-FOG than ONOFF-FOG – with the implication that these types are associated with distinct pathophysiology within the basal ganglia43. The present results also support the notion that OFF-FOG and ONOFF-FOG are likely governed by separate pathophysiological mechanisms.

We have now shown a potential neurochemical marker separating FOG levodopa responsive subtypes, whereby only the OFF-FOG group demonstrates significantly lower NA innervation. Although some investigators have suggested that FOG progresses through a continuum from OFF-FOG to ONOFF-FOG – indicating that they are not separate entities81 – others support the idea that ONOFF-FOG is an independent form that can develop without prior OFF-FOG82,83. In fact, we previously showed through detailed examination of medical records that ONOFF-FOG can appear without first transitioning through OFF-FOG43. Our results provide neurochemical support that OFF-FOG is distinct from ONOFF-FOG, as it is unlikely that over time NA innervation in the thalamus would increase in OFF-FOG patients with the development of ONOFF-FOG.

The potential of noradrenergic drugs for PD OFF-FOG

These results might suggest that NA agents would be of greater use in the subgroup of PD patients with “OFF-FOG.” While these patients are responsive to levodopa, it is often at the cost of greater dyskinesia43. While NA antagonist drugs can alleviate levodopa-induced dyskinesia in some animal models and patients84-88, the impact on causing or worsening dyskinesia is likely limited. This would make use of NA drugs reasonable alternatives. Several NA medications have been examined in a limited fashion for PD-FOG. Droxidopa was shown in a large double-blind, placebo control trial (n=218) in Japan in the 1980’s to moderately to markedly improve freezing in 25% of PD patients with FOG26. This led to approval of droxidopa for FOG in that country. The effectiveness of this drug has not been replicated4. There have also been two small pilot studies reported by Jankovic et al (n=5) and Revuelta et al (n=10) examining atomoxetine for the treatment of FOG, both showed modest benefits30,32. Finally, a multi-center, parallel-group, double-blind, placebo-controlled, randomized trial of methylphenidate (1 mg/kg per day for 90 days) for FOG in PD patients previously treated with subthalamic nucleus deep brain stimulation demonstrated that methylphenidate improved gait hypokinesia and freezing31.

Based on these results, we speculate that trials of NA agents for FOG would likely benefit from including only those patients with OFF-FOG (those with greatest decrease in NET PET signal), as it stands to reason that only these patients will likely benefit. Previous trials may have underestimated efficacy of agents if ONOFF-FOG cases were included. We consider this to be relatively likely, as patients with more severe FOG often have unresponsive FOG. Therefore, those who might have been the most likely to be recruited for trials might have been those least likely to benefit.

Non-PD FOG

In this study we included a separate group of five subjects with primary progressive freezing gait disorder (PP-FOG). Overall, the results suggest that degeneration of NA system may not significantly contribute to PP-FOG. PP-FOG is a syndrome characterized by early freezing, bradykinesia, no response to levodopa and a stereotyped course of progression45. The syndrome can be the result of several disorders, most commonly progressive supranuclear palsy42,89. Relatively little is known about this syndrome regarding pathology, pathophysiology, and neurochemistry. It is known that not all PP-FOG patients have nigrostriatal dopaminergic degeneration89, and it has been suggested that PP-FOG may result from extranigral neuronal degeneration. Based on our results, we suggest that disruption of the NA system may not contribute significantly to this type of FOG, because NET-PET binding was similar to the ONOFF-FOG and NO-FOG groups but differed from the OFF-FOG group. However, because of the small sample size, additional subjects will be needed to confirm this result, taking into consideration that multiple pathophysiological bases exist for ONOFF-FOG.

Limitations

There are some limitations to this study. The sample size was moderate, but due to the well-recognized demographic and clinical imbalances in PD patients with and without FOG, it remains difficult to completely control for potential confounds related to increased disease progression and age usually observed in FOG patients. We are encouraged by the fact that the main deficit seen in OFF-FOG was not seen in more severe ONOFF-FOG, which makes confounding by overall disease severity less likely. Because of the nature of observational studies, the potential for confounds remain, and these results should be replicated in a larger sample and preferably in a prospective context. In addition, spatial resolution of PET has reduced our ability to image certain regions such as specific nuclei of the thalamus and the LC.

Conclusion

This is the first study to examine brain NA innervation using NET-PET in PD patients with and without FOG. We found significantly decreased whole-brain NET binding in the OFF-FOG group compared to NO-FOG. Additional region-specific comparisons revealed decreased binding in the thalami, right greater than left and more notable for the PD OFF-FOG group than the ONOFF-FOG and NO-FOG groups. Based on the normal regional distribution of NA innervation and pathological studies in the thalamus of PD patients, our findings suggest that limbic pathways may play a key role in OFF-FOG in PD. This finding could have implications for clinical subtyping of FOG as well as development of therapies.

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Funding

Curtis family Fund; Sartain Lanier Family Foundation; American Parkinson’s Disease Association; NIH K25 HD086276

Competing Interests

Dr. McKay has the following competing interests: Consulting fees: Biocircuit Technologies.

Dr. Goldstein reports no competing interests.

Ms. Sommerfeld reports no competing interests.

Dr. Smith reports no competing interests.

Dr. Weinshenker reports no competing interests.

Dr. Nye reports no competing interests.

Dr. Factor has the following competing interests: Honoraria: Lundbeck, Teva, Sunovion, Biogen, Acadia, Neuroderm, Acorda, CereSpire. Grants: Ipsen, Medtronic, Boston Scientific, Teva, US World Meds, Sunovion Therapeutics, Vaccinex, Voyager, Jazz Pharmaceuticals, Lilly, CHDI Foundation, Michael J. Fox Foundation, Royalties: Demos, Blackwell Futura for textbooks, Uptodate, Other: Bracket Global LLC, CNS Ratings LLC

Supplementary material

‘Supplementary material is available at Brain online’.

Supplemental Information

Incomplete imaging data

Of N=60 participants originally enrolled in the study, NET-PET imaging was not completed for N=8 (N=1, NO-FOG; N=1, OFF-FOG; N=5, ONOFF-FOG; N=1, PP-FOG). Only partial documentation for missing data was available. Reasons for missing data were: patient moved away, N=1 NO-FOG; inability to place head in scanner, N=1 OFF-FOG, no documentation available, N = 5 ONOFF-FOG, N=1 PP-FOG. No statistically significant difference in frequency of missing imaging data was observed across study groups (P=0.61, chi-squared test).

Numerical values of NET expression

Regional standardized uptake value ratios (SUVR) extracted from the reconstructed PET data normalized to the cerebellum are shown in Table S1. Numerical values of 1.0 correspond to average expression equal to that observed in the cerebellum; numerical values ≥ 1.0 correspond to average expression greater than that observed in the cerebellum, which is considered to have negligible NET expression.

View this table:
Table S1.

Numerical NET SUVR values by study group.

Linear regression of NFOG-Q score onto right thalamus NET expression with square root transform

Because of the potential that non-normal distribution of residuals might invalidate the assumptions of linear regression, we repeated the regression analysis using square-root transformed NFOG-Q scores as the outcome variable. The results were very similar to those of the linear regression model presented in the main body of the manuscript, with a significant variation in NFOG-Q score with right thalamus NET expression in the OFF-FOG group (P=0.012) but not in the other groups. The overall variation in square root transformed NFOG-Q score explained by the model was R2adj = 0.96.

Association between MDS-UPDRS-III FOG score and right thalamus NET expression

We also examined whether right thalamus NET expression was associated with increased FOG severity as measured on the MDS-UPDRS-III. We dichotomized MDS-UPDRS-III FOG score in each of the ON and OFF states as 0-1 or ≥2 and dichotomized right thalamus NET expression about its median. Logistic regression models with terms for NET expression category and Group failed to identify statistically significant relationships in either the OFF or ON state.

Abbreviations

DβH
dopamine β-hydroxylase ()
FMT
6-[18F]fluoro-l-m-tyrosine
FOG
Freezing of gait
LED
levodopa equivalent dose
LC
Locus Ceruleus
MNI
Montreal Neurological Institute
MDS-UPDRS-III
Movement Disorder Society-Unified Parkinson’s Disease Rating Scale part III motor examination
NA
noradrenergic
NE
norepinephrine
NET
Norepinephrine Transporter
N-FOGQ
New FOG questionnaire
as NO-FOG
no freezing
OFF-FOG
those with FOG in OFF state only
ONOFF-FOG
those with FOG in the ON and OFF state
PD
Parkinson’s disease
PP-FOG
primary progressive freezing gait
SUVR
standardized uptake value ratios

References

  1. 1.↵
    Nutt JG, Bloem BR, Giladi N, Hallett M, Horak FB, Nieuwboer A. Freezing of gait: moving forward on a mysterious clinical phenomenon. Lancet neurology. 2011;10(8):734–744.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    Michalowska M, Fiszer U, Krygowska-Wajs A, Owczarek K. Falls in Parkinson’s disease. Causes and impact on patients’ quality of life. Functional neurology. 2005;20(4):163–168.
    OpenUrlPubMedWeb of Science
  3. 3.↵
    Perez-Lloret S, Negre-Pages L, Damier P, et al. Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease. JAMA neurology. 2014;71(7):884–890.
    OpenUrl
  4. 4.↵
    Fahn S. The freezing phenomenon in parkinsonism. Adv Neurol. 1995;67:53–63.
    OpenUrlPubMedWeb of Science
  5. 5.↵
    Benarroch EE. The locus ceruleus norepinephrine system: functional organization and potential clinical significance. Neurology. 2009;73(20):1699–1704.
    OpenUrlCrossRefPubMed
  6. 6.↵
    Borodovitsyna O, Duffy BC, Pickering AE, Chandler DJ. Anatomically and functionally distinct locus coeruleus efferents mediate opposing effects on anxiety-like behavior. Neurobiol Stress. 2020;13:100284.
    OpenUrl
  7. 7.
    Lewitt PA. Norepinephrine: the next therapeutics frontier for Parkinson’s disease. Translational neurodegeneration. 2012;1(1):4.
    OpenUrl
  8. 8.↵
    Aston-Jones G, Cohen JD. An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. Annu Rev Neurosci. 2005;28:403–450.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    Ordway GA, Stockmeier CA, Cason GW, Klimek V. Pharmacology and distribution of norepinephrine transporters in the human locus coeruleus and raphe nuclei. J Neurosci. 1997;17(5):1710–1719.
    OpenUrlAbstract/FREE Full Text
  10. 10.
    Tejani-Butt SM. [3H]nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. J Pharmacol Exp Ther. 1992;260(1):427–436.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    Gross-Isseroff R, Israeli M, Biegon A. Autoradiographic analysis of [3H]desmethylimipramine binding in the human brain postmortem. Brain Res. 1988;456(1):120–126.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.
    Gaspar P, Duyckaerts C, Alvarez C, Javoy-Agid F, Berger B. Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson’s disease. Annals of neurology. 1991;30(3):365–374.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    Pifl C, Kish SJ, Hornykiewicz O. Thalamic noradrenaline in Parkinson’s disease: deficits suggest role in motor and non-motor symptoms. Mov Disord. 2012;27(13):1618–1624.
    OpenUrlCrossRefPubMed
  14. 14.↵
    Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197–211.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.
    Buddhala C, Loftin SK, Kuley BM, et al. Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease. Annals of clinical and translational neurology. 2015;2(10):949–959.
    OpenUrl
  16. 16.
    Del Tredici K, Rub U, De Vos RA, Bohl JR, Braak H. Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol. 2002;61(5):413–426.
    OpenUrlCrossRefPubMed
  17. 17.↵
    Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol. 2003;60(3):337–341.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    Doppler CEJ, Kinnerup MB, Brune C, et al. Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinson’s disease. Brain. 2021;144(9):2732–2744.
    OpenUrl
  19. 19.↵
    Weinshenker D. Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease. Trends Neurosci. 2018;41(4):211–223.
    OpenUrlCrossRefPubMed
  20. 20.↵
    Rommelfanger KS, Weinshenker D, Miller GW. Reduced MPTP toxicity in noradrenaline transporter knockout mice. J Neurochem. 2004;91(5):1116–1124.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.
    Rommelfanger KS, Edwards GL, Freeman KG, Liles LC, Miller GW, Weinshenker D. Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proc Natl Acad Sci U S A. 2007;104(34):13804–13809.
    OpenUrlAbstract/FREE Full Text
  22. 22.
    Zhou C, Guo T, Wu J, et al. Locus Coeruleus Degeneration Correlated with Levodopa Resistance in Parkinson’s Disease: A Retrospective Analysis. Journal of Parkinson’s disease. 2021;11(4):1631–1640.
    OpenUrl
  23. 23.
    Bornert P, Bouret S. Locus coeruleus neurons encode the subjective difficulty of triggering and executing actions. PLoS Biol. 2021;19(12):e3001487.
    OpenUrl
  24. 24.
    Song S, Wang Q, Jiang L, et al. Noradrenergic dysfunction accelerates LPS-elicited inflammation-related ascending sequential neurodegeneration and deficits in non-motor/motor functions. Brain Behav Immun. 2019;81:374–387.
    OpenUrl
  25. 25.↵
    Rommelfanger KS, Weinshenker D. Norepinephrine: The redheaded stepchild of Parkinson’s disease. Biochem Pharmacol. 2007;74(2):177–190.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    Narabayashi H, Nakanishi, T., Yoshida, M., Yanagisawa, N., Mizuno, Y., Kanazawa, I., Kondo, T.. Therapeutic effects of L-DOPS on Parkinson’s disease: Double-blind, comparative study against placebo as control in patients with long term levodopa therapy. Rinsho Hyoka. 1987;15:423–457.
    OpenUrl
  27. 27.↵
    Fukada K, Endo T, Yokoe M, Hamasaki T, Hazama T, Sakoda S. L-threo-3,4-dihydroxyphenylserine (L-DOPS) co-administered with entacapone improves freezing of gait in Parkinson’s disease. Med Hypotheses. 2013;80(2):209–212.
    OpenUrl
  28. 28.↵
    Yamamoto M, Fujii S, Hatanaka Y. Result of long-term administration of L-threo-3,4-dihydroxyphenylserine in patients with pure akinesia as an early symptom of progressive supranuclear palsy. Clinical neuropharmacology. 1997;20(4):371–373.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    Traynor K. Droxidopa approved for neurogenic orthostatic hypotension. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2014;71(7):520.
    OpenUrl
  30. 30.↵
    Jankovic J. Atomoxetine for freezing of gait in Parkinson disease. Journal of the neurological sciences. 2009;284(1-2):177-178.
    OpenUrlCrossRefPubMed
  31. 31.↵
    Moreau C, Delval A, Defebvre L, et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson’s disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet neurology. 2012;11(7):589–596.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    Revuelta GJ, Embry A, Elm JJ, et al. Pilot study of atomoxetine in patients with Parkinson’s disease and dopa-unresponsive Freezing of Gait. Translational neurodegeneration. 2015;4:24.
    OpenUrl
  33. 33.↵
    Ono SA, Sato T, Muramatsu S. Freezing of Gait in Parkinson’s Disease Is Associated with Reduced 6-[(18)F]Fluoro-l-m-tyrosine Uptake in the Locus Coeruleus. Parkinson’s disease. 2016;2016:5430920.
    OpenUrl
  34. 34.↵
    Giladi N, Hausdorff JM. The role of mental function in the pathogenesis of freezing of gait in Parkinson’s disease. Journal of the neurological sciences. 2006;248(1-2):173–176.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    Ehgoetz Martens KA, Hall JM, Gilat M, Georgiades MJ, Walton CC, Lewis SJG. Anxiety is associated with freezing of gait and attentional set-shifting in Parkinson’s disease: A new perspective for early intervention. Gait & posture. 2016;49:431–436.
    OpenUrl
  36. 36.↵
    Ehgoetz Martens KA, Ellard CG, Almeida QJ. Does anxiety cause freezing of gait in Parkinson’s disease? PLoS One. 2014;9(9):e106561.
    OpenUrlCrossRefPubMed
  37. 37.↵
    Tillage RP, Foster SL, Lustberg D, Liles LC, McCann KE, Weinshenker D. Co-released norepinephrine and galanin act on different timescales to promote stress-induced anxiety-like behavior. Neuropsychopharmacology. 2021;46(8):1535–1543.
    OpenUrlCrossRef
  38. 38.
    McCall JG, Al-Hasani R, Siuda ER, et al. CRH Engagement of the Locus Coeruleus Noradrenergic System Mediates Stress-Induced Anxiety. Neuron. 2015;87(3):605–620.
    OpenUrlCrossRefPubMed
  39. 39.↵
    Lustberg D, Iannitelli AF, Tillage RP, Pruitt M, Liles LC, Weinshenker D. Central norepinephrine transmission is required for stress-induced repetitive behavior in two rodent models of obsessive-compulsive disorder. Psychopharmacology (Berl). 2020;237(7):1973–1987.
    OpenUrlCrossRefPubMed
  40. 40.↵
    Brumberg J, Tran-Gia J, Lapa C, Isaias IU, Samnick S. PET imaging of noradrenaline transporters in Parkinson’s disease: focus on scan time. Ann Nucl Med. 2019;33(2):69–77.
    OpenUrl
  41. 41.↵
    Ding YS, Lin KS, Logan J, Benveniste H, Carter P. Comparative evaluation of positron emission tomography radiotracers for imaging the norepinephrine transporter: (S,S) and (R,R) enantiomers of reboxetine analogs ([11C]methylreboxetine, 3-Cl-[11C]methylreboxetine and [18F]fluororeboxetine), (R)-[11C]nisoxetine, [11C]oxaprotiline and [11C]lortalamine. J Neurochem. 2005;94(2):337–351.
    OpenUrlCrossRefPubMed
  42. 42.↵
    Factor SA, Higgins DS, Qian J. Primary progressive freezing gait: a syndrome with many causes. Neurology. 2006;66(3):411–414.
    OpenUrl
  43. 43.↵
    McKay JL, Goldstein FC, Sommerfeld B, Bernhard D, Perez Parra s, SA. F. Freezing of Gait can persist after an acute levodopa challenge in Parkinson’s disease. NPJ Parkinson’s disease. 2019;5(25).
  44. 44.↵
    Hughes AJ, Daniel, S.E., Kilford, L., Lees, A. J. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181–184.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    Factor SA, Jennings DL, Molho ES, Marek KL. The natural history of the syndrome of primary progressive freezing gait. Arch Neurol. 2002;59(11):1778–1783.
    OpenUrlCrossRefPubMedWeb of Science
  46. 46.↵
    Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord. 1992;7(1):2–13.
    OpenUrlCrossRefPubMedWeb of Science
  47. 47.↵
    Schou M, Halldin C, Sovago J, et al. Specific in vivo binding to the norepinephrine transporter demonstrated with the PET radioligand, (S,S)-[11C]MeNER. Nucl Med Biol. 2003;30(7):707–714.
    OpenUrlCrossRefPubMed
  48. 48.↵
    de Jong HW, van Velden FH, Kloet RW, Buijs FL, Boellaard R, Lammertsma AA. Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner. Phys Med Biol. 2007;52(5):1505–1526.
    OpenUrlCrossRefPubMedWeb of Science
  49. 49.↵
    Mugler JP, 3rd.. Overview of MR imaging pulse sequences. Magnetic resonance imaging clinics of North America. 1999;7(4):661–697.
    OpenUrlPubMed
  50. 50.↵
    Lusebrink F, Wollrab A, Speck O. Cortical thickness determination of the human brain using high resolution 3T and 7T MRI data. Neuroimage. 2013;70:122–131.
    OpenUrlCrossRefPubMedWeb of Science
  51. 51.↵
    Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15(1):273–289.
    OpenUrlCrossRefPubMedWeb of Science
  52. 52.↵
    Adhikarla V, Zeng F, Votaw JR, Goodman MM, Nye JA. Compartmental modeling of [(11)C]MENET binding to the norepinephrine transporter in the healthy human brain. Nucl Med Biol. 2016;43(5):318–323.
    OpenUrl
  53. 53.↵
    Hatcher-Martin JM, McKay JL, Pybus AF, et al. Cerebrospinal fluid biomarkers in Parkinson’s disease with freezing of gait: an exploratory analysis. NPJ Parkinson’s disease. 2021;7(1):105.
    OpenUrl
  54. 54.↵
    Duffy KB, Ray B, Lahiri DK, et al. Effects of Reducing Norepinephrine Levels via DSP4 Treatment on Amyloid-beta Pathology in Female Rhesus Macaques (Macaca Mulatta). Journal of Alzheimer’s disease : JAD. 2019;68(1):115–126.
    OpenUrl
  55. 55.
    Heneka MT, Ramanathan M, Jacobs AH, et al. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci. 2006;26(5):1343–1354.
    OpenUrlAbstract/FREE Full Text
  56. 56.↵
    Jardanhazi-Kurutz D, Kummer MP, Terwel D, et al. Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits. Neurochem Int. 2010;57(4):375–382.
    OpenUrlCrossRefPubMedWeb of Science
  57. 57.↵
    Heneka MT, Nadrigny F, Regen T, et al. Locus ceruleus controls Alzheimer’s disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci U S A. 2010;107(13):6058–6063.
    OpenUrlAbstract/FREE Full Text
  58. 58.↵
    D’Cruz N, Vervoort G, Chalavi S, Dijkstra BW, Gilat M, Nieuwboer A. Thalamic morphology predicts the onset of freezing of gait in Parkinson’s disease. NPJ Parkinson’s disease. 2021;7(1):20.
    OpenUrl
  59. 59.↵
    Fling BW, Cohen RG, Mancini M, Nutt JG, Fair DA, Horak FB. Asymmetric pedunculopontine network connectivity in parkinsonian patients with freezing of gait. Brain. 2013;136(Pt 8):2405-2418.
    OpenUrlCrossRefPubMedWeb of Science
  60. 60.↵
    Wang M, Jiang S, Yuan Y, et al. Alterations of functional and structural connectivity of freezing of gait in Parkinson’s disease. Journal of neurology. 2016;263(8):1583–1592.
    OpenUrlCrossRefPubMed
  61. 61.↵
    Shine JM, Matar E, Ward PB, et al. Exploring the cortical and subcortical functional magnetic resonance imaging changes associated with freezing in Parkinson’s disease. Brain. 2013;136(Pt 4):1204–1215.
    OpenUrlCrossRefPubMedWeb of Science
  62. 62.↵
    Lewis SJ, Barker RA. A pathophysiological model of freezing of gait in Parkinson’s disease. Parkinsonism & related disorders. 2009;15(5):333–338.
    OpenUrl
  63. 63.↵
    Perez-Santos I, Palomero-Gallagher N, Zilles K, Cavada C. Distribution of the Noradrenaline Innervation and Adrenoceptors in the Macaque Monkey Thalamus. Cereb Cortex. 2021;31(9):4115–4139.
    OpenUrl
  64. 64.↵
    Oke AF, Carver LA, Gouvion CM, Adams RN. Three-dimensional mapping of norepinephrine and serotonin in human thalamus. Brain Res. 1997;763(1):69–78.
    OpenUrlCrossRefPubMedWeb of Science
  65. 65.↵
    Oke A, Keller R, Mefford I, Adams RN. Lateralization of norepinephrine in human thalamus. Science. 1978;200(4348):1411–1413.
    OpenUrlAbstract/FREE Full Text
  66. 66.↵
    Ehgoetz Martens KA, Hall JM, Georgiades MJ, et al. The functional network signature of heterogeneity in freezing of gait. Brain. 2018;141(4):1145–1160.
    OpenUrl
  67. 67.↵
    McFarland NR, Haber SN. Organization of thalamostriatal terminals from the ventral motor nuclei in the macaque. J Comp Neurol. 2001;429(2):321–336.
    OpenUrlCrossRefPubMedWeb of Science
  68. 68.↵
    McFarland NR, Haber SN. Thalamic relay nuclei of the basal ganglia form both reciprocal and nonreciprocal cortical connections, linking multiple frontal cortical areas. J Neurosci. 2002;22(18):8117–8132.
    OpenUrlAbstract/FREE Full Text
  69. 69.↵
    Muller ML, Albin RL, Kotagal V, et al. Thalamic cholinergic innervation and postural sensory integration function in Parkinson’s disease. Brain. 2013;136(Pt 11):3282–3289.
    OpenUrlCrossRefPubMed
  70. 70.↵
    Rub U, Del Tredici K, Schultz C, et al. Parkinson’s disease: the thalamic components of the limbic loop are severely impaired by alpha-synuclein immunopositive inclusion body pathology. Neurobiol Aging. 2002;23(2):245–254.
    OpenUrlCrossRefPubMedWeb of Science
  71. 71.↵
    Diederich NJ, Goldman JG, Stebbins GT, Goetz CG. Failing as doorman and disc jockey at the same time: Amygdalar dysfunction in Parkinson’s disease. Mov Disord. 2016;31(1):11–22.
    OpenUrl
  72. 72.
    Vriend C, Boedhoe PS, Rutten S, Berendse HW, van der Werf YD, van den Heuvel OA. A smaller amygdala is associated with anxiety in Parkinson’s disease: a combined FreeSurfer-VBM study. J Neurol Neurosurg Psychiatry. 2016;87(5):493–500.
    OpenUrlAbstract/FREE Full Text
  73. 73.
    He Y, Xu T, Zhang W, Zuo XN. Lifespan anxiety is reflected in human amygdala cortical connectivity. Hum Brain Mapp. 2016;37(3):1178–1193.
    OpenUrlCrossRefPubMed
  74. 74.
    Marchand WR. Cortico-basal ganglia circuitry: a review of key research and implications for functional connectivity studies of mood and anxiety disorders. Brain Struct Funct. 2010;215(2):73–96.
    OpenUrlPubMed
  75. 75.↵
    Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005;128(Pt 6):1314–1322.
    OpenUrlCrossRefPubMedWeb of Science
  76. 76.↵
    Gilat M, Ehgoetz Martens KA, Miranda-Dominguez O, et al. Dysfunctional Limbic Circuitry Underlying Freezing of Gait in Parkinson’s Disease. Neuroscience. 2018;374:119–132.
    OpenUrl
  77. 77.↵
    Lewis SJ, Barker RA. A pathophysiological model of freezing of gait in Parkinson’s disease. Parkinsonism & related disorders. 2009;15(5):333–338.
    OpenUrl
  78. 78.↵
    Lewis SJ, Shine JM. The Next Step: A Common Neural Mechanism for Freezing of Gait. Neuroscientist. 2016;22(1):72–82.
    OpenUrlCrossRefPubMed
  79. 79.↵
    Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, Garcia-Urra D. “Panic attacks” in Parkinson’s disease. A long-term complication of levodopa therapy. Acta neurologica Scandinavica. 1993;87(1):14–18.
    OpenUrlCrossRefPubMed
  80. 80.↵
    Factor SA, Scullin MK, Sollinger AB, et al. Freezing of gait subtypes have different cognitive correlates in Parkinson’s disease. Parkinsonism & related disorders. 2014;20(12):1359–1364.
    OpenUrl
  81. 81.↵
    Nonnekes J, Snijders AH, Nutt JG, Deuschl G, Giladi N, Bloem BR. Freezing of gait: a practical approach to management. Lancet neurology. 2015;14(7):768–778.
    OpenUrlCrossRef
  82. 82.↵
    Espay AJ, Fasano A, van Nuenen BF, Payne MM, Snijders AH, Bloem BR. “On” state freezing of gait in Parkinson disease: a paradoxical levodopa-induced complication. Neurology. 2012;78(7):454–457.
    OpenUrlCrossRefPubMed
  83. 83.↵
    Snijders AH, Takakusaki K, Debu B, et al. Physiology of freezing of gait. Annals of neurology. 2016;80(5):644–659.
    OpenUrlCrossRefPubMed
  84. 84.↵
    Bhide N, Lindenbach D, Barnum CJ, George JA, Surrena MA, Bishop C. Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat. J Neurochem. 2015;134(2):222–232.
    OpenUrl
  85. 85.
    Lindenbach D, Ostock CY, Eskow Jaunarajs KL, et al. Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat. J Pharmacol Exp Ther. 2011;337(3):755–765.
    OpenUrlAbstract/FREE Full Text
  86. 86.
    Shi Z, Bamford IJ, McKinley JW, Devi SPS, Vahedipour A, Bamford NS. Propranolol Relieves L-Dopa-Induced Dyskinesia in Parkinsonian Mice. Brain Sci. 2020;10(12).
  87. 87.
    Rascol O, Arnulf I, Peyro-Saint Paul H, et al. Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson’s disease. Mov Disord. 2001;16(4):708–713.
    OpenUrlCrossRefPubMedWeb of Science
  88. 88.↵
    Carpentier AF, Bonnet AM, Vidailhet M, Agid Y. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson’s disease. Neurology. 1996;46(6):1548–1551.
    OpenUrlCrossRef
  89. 89.↵
    Fasano A, Baldari S, Di Giuda D, et al. Nigro-striatal involvement in primary progressive freezing gait: insights into a heterogeneous pathogenesis. Parkinsonism & related disorders. 2012;18(5):578–584.
    OpenUrl
Back to top
Posted March 15, 2022.
Download PDF
Data/Code
Email
Reduced Norepinephrine Transporter Binding in Parkinson’s disease with dopa Responsive Freezing Gait
J. Lucas McKay, Jonathan Nye, Felicia C. Goldstein, Barbara Sommerfeld, Yoland Smith, David Weinshenker, Stewart A. Factor
medRxiv 2022.03.14.22272365; doi: https://doi.org/10.1101/2022.03.14.22272365
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area